|Revised response criteria for malignant lymphoma|
BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ...
Journal of clinical oncology 25 (5), 579-586, 2007
|Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients …|
W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, ...
Blood 106 (12), 3725-3732, 2005
|Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma|
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
|PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma|
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
|A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma|
E Hoster, M Dreyling, W Klapper, C Gisselbrecht, A Van Hoof, ...
Blood, The Journal of the American Society of Hematology 111 (2), 558-565, 2008
|Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ...
Annals of Oncology 32 (1), 23-33, 2021
|Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long …|
G Lenz, M Dreyling, E Hoster, B Wörmann, U Dührsen, B Metzner, ...
Journal of Clinical Oncology 23 (9), 1984-1992, 2005
|The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with …|
R Forstpointner, M Dreyling, R Repp, S Hermann, A Hänel, B Metzner, ...
Blood 104 (10), 3064-3071, 2004
|Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in …|
M Dreyling, G Lenz, E Hoster, A Van Hoof, C Gisselbrecht, R Schmits, ...
Blood 105 (7), 2677-2684, 2005
|The landscape of genomic alterations across childhood cancers|
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
|Treatment of older patients with mantle-cell lymphoma|
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
|Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
|Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide …|
R Forstpointner, M Unterhalt, M Dreyling, HP Böck, R Repp, H Wandt, ...
Blood 108 (13), 4003-4008, 2006
|Improvement of overall survival in advanced stage mantle cell lymphoma|
A Herrmann, E Hoster, T Zwingers, G Brittinger, M Engelhard, P Meusers, ...
Journal of Clinical Oncology 27 (4), 511-518, 2009
|Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis|
H Schulz, JF Bohlius, S Trelle, N Skoetz, M Reiser, T Kober, G Schwarzer, ...
Journal of the National Cancer Institute 99 (9), 706-714, 2007
|Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective …|
A Pastore, V Jurinovic, R Kridel, E Hoster, AM Staiger, M Szczepanowski, ...
The lancet oncology 16 (9), 1111-1122, 2015
|Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era|
P Pérez-Galán, M Dreyling, A Wiestner
Blood, The Journal of the American Society of Hematology 117 (1), 26-38, 2011
|Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network|
M Tiemann, C Schrader, W Klapper, MH Dreyling, E Campo, A Norton, ...
British journal of haematology 131 (1), 29-38, 2005
|Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a …|
G Lenz, M Dreyling, E Schiegnitz, R Forstpointner, H Wandt, M Freund, ...
Blood 104 (9), 2667-2674, 2004
|Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study|
M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ...
The Lancet 387 (10020), 770-778, 2016